Virttu: TNK Therapeutics to acquire Glasgow based biopharma company Virttu Biologics
TNK Therapeutics Inc. a subsidiary of Sorrento Therapeutics Inc. has entered into a binding term sheet to acquire Virttu Biologics Limited Virttu.
Read full article »
CEO
Virttu is engaged in the discovery and development of oncolytic immunotherapy for the treatment of cancer.
Read more